Arcadia Investment Management Corp MI Invests $147,000 in Natera, Inc. (NASDAQ:NTRA)

Arcadia Investment Management Corp MI purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 931 shares of the medical research company’s stock, valued at approximately $147,000.

Several other large investors have also recently modified their holdings of the stock. Boston Financial Mangement LLC purchased a new position in shares of Natera in the 4th quarter worth about $225,000. Handelsbanken Fonder AB raised its position in shares of Natera by 2.3% in the 4th quarter. Handelsbanken Fonder AB now owns 104,100 shares of the medical research company’s stock worth $16,479,000 after purchasing an additional 2,300 shares during the last quarter. Ieq Capital LLC raised its position in shares of Natera by 551.2% in the 4th quarter. Ieq Capital LLC now owns 61,005 shares of the medical research company’s stock worth $9,657,000 after purchasing an additional 51,637 shares during the last quarter. Global Retirement Partners LLC increased its holdings in Natera by 55.0% in the 4th quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company’s stock worth $69,000 after buying an additional 154 shares in the last quarter. Finally, Convergence Investment Partners LLC increased its holdings in Natera by 41.1% in the 4th quarter. Convergence Investment Partners LLC now owns 2,757 shares of the medical research company’s stock worth $436,000 after buying an additional 803 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Natera stock opened at $168.19 on Friday. The business has a 50-day simple moving average of $168.06 and a two-hundred day simple moving average of $144.78. Natera, Inc. has a 52-week low of $69.14 and a 52-week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Insider Activity

In other news, insider Solomon Moshkevich sold 4,858 shares of Natera stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $166.59, for a total transaction of $809,294.22. Following the transaction, the insider now directly owns 114,912 shares of the company’s stock, valued at $19,143,190.08. The trade was a 4.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Roelof Botha sold 87,473 shares of Natera stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $169.12, for a total value of $14,793,433.76. Following the transaction, the director now directly owns 1,224,787 shares in the company, valued at approximately $207,135,977.44. The trade was a 6.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 295,772 shares of company stock valued at $49,741,699 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Barclays assumed coverage on Natera in a report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective for the company. TD Cowen lifted their price objective on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. The Goldman Sachs Group lifted their price objective on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Canaccord Genuity Group lifted their price objective on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, Morgan Stanley lifted their price objective on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $170.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.